research must be done in determining the effectiveness and increased safety of using liposomal
formulations of other chemotherapeutic drugs. So far, one of the only chemotherapy drugs that have a
commercially available liposomal formulation is doxorubicin. Hence, it would be beneficial to
develop more drugs with liposomal formulations to reduce systemic side effects. Liposome
technology for targeted drug delivery is the future of pharmaceuticals.
In addition, we believe that future studies should be conducted using the design used by Cortes, et al.
in their study, in order to find the determining factors to obtain the high overall response rate. This
could improve the efficacy of the treatment in the future.
5. Conclusion
From the obtained results from the systematic review, it can be concluded that a combination of
trastuzumab with liposomal doxorubicin is a safe and effective treatment regimen for advanced stage
breast cancer. This conclusion shows great potential for future research in the treatment of breast
cancer, as well as for the development of new liposomal formulations of various drugs with known
adverse systemic side effects.
References
Allen, Theresa M., and Francis J. Martin. "Advantages of liposomal delivery systems for
anthracyclines." Seminars in oncology. Vol. 31. WB Saunders, 2004.
Cardinale, D., Colombo, A., Torrisi, R., Sandri, M. T., Civelli, M., Salvatici, M., ... & Cipolla, C. M.
(2010). Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin
I evaluation. Journal of Clinical Oncology, 28(25), 3910-3916.
Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010). Doxorubicin cardiomyopathy.
Cardiology, 115(2), 155-162.
Chia, S., Clemons, M., Martin, L. A., Rodgers, A., Gelmon, K., Pond, G. R., & Panasci, L. (2006).
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast
cancer: a multicenter phase II trial. Journal of clinical oncology, 24(18), 2773-2778.
Cortes, J., Di Cosimo, S., Climent, M. A., Cortés-Funes, H., Lluch, A., Gascón, P., ... & Baselga, J.
(2009). Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in
HER-2-overexpre ssing breast cancer: a multicenter phase I/II study. Clinical Cancer Research,
15(1), 307-314.
De Rosa, G., Salzano, G., Caraglia, M., & Abbruzzese, A. (2012). Nanotechnologies: a strategy to
overcome blood-brain barrier. Current drug metabolism, 13(1), 61-69. Deshpande, Pranali P.,